Abstract
Hyperkalaemia is a common, treatable, medical emergency, often with an iatrogenic cause. This case illustrates the vulnerability of patients with pre-existing renal tubular acidosis type 4 to medications that further inhibit renin-aldosterone action. The case also illustrates the danger of keeping entirely separate case notes between different hospital disciplines.
[download-attachments container="div" style="list" dipslay_icon="1" display_count="1" display__size="0"]
References
- Siamopoulos KC, Elisaf M, Katopodis K. Iatrogenic Hyperkalaemia – points to consider in diagnosis and management. Nephrology Dialysis Transplantation 1997; 13: 2402-2406
- Warren SE, O’Connor DT. Hyperkalemia resulting from captopril administration. JAMA 1980: 22; 2551-2
- Textror SC, Bravo EL, Fouad FM, et al. Hyperkalaemia in azotemic patients during ACE inhibition and aldosterone reduction with captopril. Am J Med. 1982; 73: 719-725
- Choi MJ, Fernandez PC, Patniak A et al. Trimethoprim-induced hyperkalaemia in a patient with AIDS. N Engl J Med 1993; 328: 703-706.
- Velázquez H, Perazella MA, Wright FS, et al. Renal mechanism of trimethoprim induced hyperkalaemia. Ann Intern Med 1993; 119: 296-301
- Schreiber M, Schlanger LE, Chen CB et al. Antikaliuretic action of trimethoprim is minimized by raising urinary pH. Kidney Int 1996; 50: 2063-2069
- Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol 1996; 46: 187-82
- Secondary prevention in primary and secondary care for patients following a myocardial infarction. NICE CG48. May 2007.
Request Permissions
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center’s (CCC) Marketplace website by clicking the button below:
